ANDA/Patent Bill negotiations
Sen. Hatch (R-Utah), explaining his ANDA/patent legislation (S 2926) just before it passed the Senate Aug. 10 ("The Pink Sheet" Aug. 13, p. 11), acknowledged the help of several parties to the negotiations. He cited Warner-Lambert President Joseph Williams, American Home Products Chief Exec Jack Stafford, Generic Pharmaceutical Industry Assn. President Bill Haddad, Bristol-Myers Vice President William Greif, J&J Asst. General Counsel William Ryan, and "above all . . . the flexibility and leadership" of Rep. Waxman (D-Calif.).
You may also be interested in...
Technology modernization efforts, the expansion of cloud-based submission capabilities, and the ongoing COVID-19 pandemic could serve as catalysts to broaden FDA’s Real-Time Oncology Review program beyond cancer therapeutics, Pfizer exec Richard Jahn says.
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.